The Preventive Coronary Intervention on Stenosis With Functionally Insignificant Vulnerable Plaque

Asan Medical Center0 个研究点目标入组 1,600 人开始时间: 待定最近更新: 2020年4月21日

试验速览

暂无简介。

•Age 19 years or older
•Symptomatic or asymptomatic coronary artery disease patients
•Patients having at least one significant stenosis (diameter stenosis > 50%) with FFR >0.80 and meeting two of the following:
•MLA(minimal luminal area)<4mm2
•plaque burden>70%
•Lipid-rich plaque on NIRS(Intracoronary Near-Infrared Spectroscopy) (defined as maxLCBI4mm>315)
•TCFA(thin-cap fibroatheroma) defined by OCT(fibrous cap thickness<65µm and arc>90°) or VH-IVUS=10% confluent NC with>30° abutting to the lumen in 3 consecutive slices)
•2 target vulnerable lesions
•Eligible for percutaneous coronary intervention with Absorb Bioresorbable Vascular Scaffold or Everolimus Eluting Stent
•Willing and able to provide informed written consent
•Reference vessel diameter 2.75-4.0
•Lesion length = 40

•Patients in whom the preferred treatment is CABG(Coronary artery bypass grafting)
•Stented lesion
•Bypass graft lesion
•The patients who have more than or equal to 3 target lesions
•2 target lesions in the same coronary territory
•Heavily calcified or angulated lesion
•Bifurcation lesion requiring 2 stenting technique
•Contraindication to or planned discontinuation of dual antiplatelet therapy within 1 year
•Life expectancy less than 2 years
•Planned cardiac surgery or planned major non cardiac surgery
•Woman who are breastfeeding, pregnant or planning to become pregnant during the course of the study

发起方